Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931688 | 0.89 | CYP3A4 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL2931686 | 0.76 | CYP3A4 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL2935375 | 0.75 | LMNA (0.36) | KDM4EALDH1A1 | |
| SCHEMBL2101678 | 0.73 | ALDH1A1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL2929561 | 0.70 | KMT2A (0.40) | — | |
| SCHEMBL2933125 | 0.68 | EGFR (0.42) | — | |
| SCHEMBL2102887 | 0.67 | ADORA2A (0.36) | ALDH1A1 | |
| SCHEMBL2937613 | 0.65 | NPC1 (0.42) | — | |
| SCHEMBL2099208 | 0.64 | CES2 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL5735332 | 0.63 | CYP3A4 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7138426-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1501819-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050234245-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1501819-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091239-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234245-A1 | Estrogen receptor modulators | ESRRB, ESR2, GPER1 | KDM4E 246/4885ALDH1A1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.